Stay updated on Cabozantinib in RCC After Checkpoint Inhibitors Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in RCC After Checkpoint Inhibitors Clinical Trial page.

Latest updates to the Cabozantinib in RCC After Checkpoint Inhibitors Clinical Trial page
- CheckyesterdayChange DetectedThe webpage has updated its date-related content, adding new dates in May 2025 while removing older dates from March and early April 2025.SummaryDifference0.2%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the detailed study objectives and inclusion/exclusion criteria for a clinical trial involving cabozantinib for renal cell carcinoma. Additionally, the version number has been updated from v2.14.4 to v2.15.0.SummaryDifference34%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4 and has added new dates for future events while removing some past dates.SummaryDifference0.5%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version and a new posting date, indicating a revision from v2.14.2 to v2.14.3 and a change in the last update date to March 25, 2025.SummaryDifference0.3%
- Check59 days agoChange DetectedThe page has updated its date information, adding new dates in March and December 2025 while removing older dates from February 2025 and a date in September 2099.SummaryDifference0.3%
Stay in the know with updates to Cabozantinib in RCC After Checkpoint Inhibitors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in RCC After Checkpoint Inhibitors Clinical Trial page.